Clinical Trials

608 enrolled 17 charts

Breast Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT01196390 2026-02-18

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

203 enrolled 22 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT05415215 2026-02-10

ProHer

346 enrolled 20 charts

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

190 enrolled 12 charts

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

305 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01772472 2025-07-22

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

1,486 enrolled 37 charts 1 FDA

Breast Neoplasms

NCT01275677 2025-07-14

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

3,270 enrolled 16 charts

Breast Neoplasms

NCT00769379 2025-06-12

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

2,014 enrolled 16 charts

Carcinoma, Intraductal, Noninfiltrating

NCT00520975 2025-03-28

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

96 enrolled 16 charts

Breast Neoplasms

NCT00490139 2025-03-21

ALTTO

8,381 enrolled 22 charts

Breast Neoplasms

NCT00667251 2025-03-21

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

652 enrolled 50 charts

Breast Neoplasms

NCT02492711 2025-03-17

SOPHIA

624 enrolled 17 charts 2 FDA

Tumor-Agnostic

Neoplasm Metastasis

NCT01160211 2025-03-07

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

369 enrolled 19 charts

Breast Neoplasms

NCT01084876 2025-02-11

Compare

475 enrolled 25 charts

Breast Neoplasms

NCT03726879 2024-11-05

IMpassion050

454 enrolled 28 charts

Breast Neoplasms

NCT03425656 2024-06-28

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

108 enrolled 7 charts

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

500 enrolled 28 charts 2 FDA

Breast Neoplasms

NCT03084237 2024-05-17

Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

652 enrolled 15 charts

Breast Neoplasms

NCT01120184 2024-03-04

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

1,095 enrolled 46 charts

Breast Neoplasms

NCT02586025 2023-05-22

PEONY

329 enrolled 33 charts

Breast Neoplasms

NCT00272987 2023-04-28

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

63 enrolled 22 charts

Breast Neoplasms

NCT01875367 2023-04-05

ChangHER-SC

166 enrolled 24 charts

Breast Neoplasms

NCT02162667 2022-08-03

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

562 enrolled 15 charts

HER2-positive Carcinoma of Breast

NCT03556358 2022-01-14

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

809 enrolled 14 charts

Breast Neoplasms

NCT02896855 2021-12-16

PUFFIN

243 enrolled 23 charts

Breast Neoplasms

NCT00553358 2021-09-21

Neo ALTTO

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

NCT01989676 2021-07-06

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

707 enrolled 20 charts

Breast Neoplasms

NCT01566721 2021-04-27

SafeHER

2,577 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT01940497 2020-11-03

SCHEARLY

240 enrolled 14 charts

Breast Neoplasms

NCT01572038 2020-09-25

PERUSE

1,436 enrolled 53 charts

Breast Neoplasms

NCT01926886 2019-09-18

A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)

102 enrolled 8 charts

Breast Neoplasms

NCT01901146 2019-08-07

Lilac

725 enrolled 18 charts

Breast Neoplasms

NCT01125566 2019-07-18

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

508 enrolled 13 charts

Breast Neoplasms

NCT00968968 2019-06-10

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

37 enrolled 11 charts

Tumor-Agnostic

Carcinoma, Neoplasms

NCT00820222 2019-04-02

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

540 enrolled 18 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00876395 2018-12-19

BOLERO-1

719 enrolled 25 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01764022 2018-11-29

A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients

225 enrolled 23 charts

Breast Neoplasms

NCT02149524 2018-10-24

A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

875 enrolled 12 charts

HER2 Positive Early or Locally Advanced Breast Cancer

NCT02019277 2018-09-13

SAPPHIRE

50 enrolled 18 charts

Breast Neoplasms

NCT01026142 2018-08-14

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

452 enrolled 18 charts

Breast Neoplasms

NCT00950300 2018-01-23

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

596 enrolled 31 charts 1 FDA

Breast Neoplasms

NCT01007942 2017-04-05

BOLERO-3

569 enrolled 16 charts

Breast Neoplasms

NCT02721641 2017-03-31

A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer

69 enrolled 5 charts

Tumor-Agnostic

Neoplasms

NCT02144012 2017-03-07

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer

49 enrolled 16 charts

Breast Neoplasms

NCT00021255 2016-11-15

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

3,222 enrolled 10 charts

Breast Neoplasms

NCT00320385 2016-02-26

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

296 enrolled 13 charts

Breast Neoplasms

NCT00391092 2015-08-28

A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

424 enrolled 12 charts

Breast Neoplasms

NCT01998906 2014-10-28

A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer

330 enrolled 22 charts